TCGA-90-A4EE-01A-11R-A24Z-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 53
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- ALLOGRAFT_REJECTION+0.500
- INTERFERON_GAMMA_RESPONSE+0.490
- INTERFERON_ALPHA_RESPONSE+0.460
- E2F_TARGETS+0.370
- MYC_TARGETS_V1+0.340
- IL6_JAK_STAT3_SIGNALING+0.320
- G2M_CHECKPOINT+0.290
- INFLAMMATORY_RESPONSE+0.180
- TNFA_SIGNALING_VIA_NFKB+0.130
Top 10 suppressed
- TGF_BETA_SIGNALING-0.500
- PROTEIN_SECRETION-0.370
- ANDROGEN_RESPONSE-0.350
- ESTROGEN_RESPONSE_EARLY-0.340
- ESTROGEN_RESPONSE_LATE-0.320
- GLYCOLYSIS-0.320
- UV_RESPONSE_DN-0.320
- ADIPOGENESIS-0.300
- FATTY_ACID_METABOLISM-0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-00497 | — | cohortSQ1 | 0.907 |
| 2 | MBCproject_0095_T3_RNA | — | E | 0.872 |
| 3 | SRR8518253 | — | D | 0.867 |
| 4 | MBCProject_5971_T1_RNA | — | D | 0.843 |
| 5 | TCGA-EW-A1OV-01A-11R-A144-07 | — | D | 0.841 |
| 6 | SRR8613746 | — | D | 0.835 |
| 7 | TCGA-E2-A1B6-01A-31R-A12P-07 | — | D | 0.833 |
| 8 | TCGA-E2-A1II-01A-11R-A144-07 | — | E | 0.833 |
| 9 | TCGA-BH-A0B9-01A-11R-A056-07 | — | E | 0.831 |
| 10 | SRR8518222 | — | D | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| COMPLEMENT | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.020 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |